Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.

Cell cycle (Georgetown, Tex.) - 1 Jun 2007

Hucl Tomas, Gallmeier Eike, Kern Scott E

Abstract excerpt

Single therapeutic agents very often fail in unselected patients. It is therefore commonplace to combine an agent specifically with a selected patient subgroup or with another agent. To support such efforts, it is useful to clarify the distinctions between the terms and the mathematical models us...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Drug Evaluation, Preclinical
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to Inhibitory Concentration 50

Share to Patient Selection

Share to Terminology as Topic

Source

Identifiers

PMID: 17568192
DOI: 10.4161/cc.6.11.4359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17568192-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.PMID 17568192Read ↗

Defining principles of combination drug mechanisms of action.Semantic proximity Read ↗

Correlated Drug Action as a Baseline Model for Combination Therapy in Patient Cohorts and Cell CulturesSemantic proximity Read ↗

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenograftsSemantic proximity Read ↗

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenograftsSemantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

Diverse array-designed modes of combination therapies in Fangjiomics.Semantic proximity Read ↗

metascreen: A modular tool for the design and analysis of drug combination screensSemantic proximity Read ↗

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.Semantic proximity Read ↗

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read ↗

Multiobjective Optimization Identifies Cancer-Selective Combination TherapiesSemantic proximity Read ↗

Phenotypic response surfaces in pharmacology: Mechanistic and translational perspectives on optimizing drug combination therapies.Semantic proximity Read ↗

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.